BridgeBio Oncology Therapeutics, Inc.

Clinical-stage biopharma creating small molecule drugs for RAS-dependent cancers.

BBOT | NDAQ

Overview

Corporate Details

ISIN(s):: N/A
LEI:
Country:: United States of America
Address:: 256 E. GRAND AVENUE, SUITE 104, 94080 SOUTH SAN FRANCISCO
Website:: https://bbotx.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

BridgeBio Oncology Therapeutics, Inc. (BBOT) is a clinical-stage biopharmaceutical company advancing a pipeline of novel small molecule therapeutics for precision oncology. The company leverages an expert understanding of RAS signaling biology to inform rational drug design, with a focus on treating RAS-dependent cancers. Its approach aims to maximize target inhibition by developing therapies that can inhibit a broad spectrum of KRAS mutants in both their active (ON) and inactive (OFF) states, as well as target RAS-driven PI3K activation. The company's mission is to translate this scientific knowledge into transformative medicines for patients with cancers that have clear genetic drivers.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all BridgeBio Oncology Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for BridgeBio Oncology Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for BridgeBio Oncology Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
2cureX AB Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.	Sweden	2CUREX
4BASEBIO PLC Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.	United Kingdom	4BB
4SC AG Developing small-molecule epigenetic drugs for high-need cancer indications.	Germany	VSC
60 DEGREES PHARMACEUTICALS, INC. Develops medicines for tropical diseases, including ARAKODA for malaria prevention.	United States of America	SXTP
89bio, Inc. Developing therapies for liver and cardiometabolic diseases like MASH and SHTG.	United States of America	ETNB
Aardvark Therapeutics, Inc. Developing oral drugs to suppress appetite for obesity and rare metabolic diseases.	United States of America	AARD
AbbVie Inc. A research-based biopharma firm creating medicines for immunology, oncology, and neuroscience.	United States of America	ABBV
ABEONA THERAPEUTICS INC. Developing AAV-based cell and gene therapies for serious and rare diseases.	United States of America	ABEO
Abera Bioscience AB Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.	Sweden	ABERA
ABINGDON HEALTH PLC A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.	United Kingdom	ABDX